aluates Reports

$ 0.0

Automative

Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Research Report 2025

Published Date: March 2025

Report Code: QYRE-Auto-26P18765

BUY CHAPTERS

Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Research Report 2025

Code: QYRE-Auto-26P18765

Report

March 2025

Pages:100

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Companies

Lonza Group

Merck KGaA

WuXi XDC

AbbVie

Piramal Pharma Solutions

Catalent

Sterling Pharma Solutions

Axplora

Aji Bio-Pharma

BSP Pharmaceuticals

Cerbios-Pharma

Goodwin Biotechnology

TOT BIOPHARM

Huadong Medicine

Innovent Biologics

Shanghai Henlius Biotech

Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size

The global market for Antibody-drug Conjugates (ADCs) CMO and CDMO was valued at US$ 3863 million in the year 2024 and is projected to reach a revised size of US$ 12840 million by 2031, growing at a CAGR of 19.0% during the forecast period.

Antibody-drug Conjugates (ADCs) CMO and CDMO Market

Antibody-drug conjugates (ADCs) are a type of targeted biologics that connect cytotoxic drugs to monoclonal antibodies through linkers, which can be efficiently transported to target tumor cells to exert anti-tumor effects. CMO and CDMO companies specialize in drug production services, with a main focus on customized production during drug research and development and commercial production after market launch.

North American market for Antibody-drug Conjugates (ADCs) CMO and CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Antibody-drug Conjugates (ADCs) CMO and CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global market for Antibody-drug Conjugates (ADCs) CMO and CDMO in Solid Tumors is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Antibody-drug Conjugates (ADCs) CMO and CDMO include Lonza Group, Merck KGaA, WuXi XDC, Abbvie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions, Axplora, Aji Bio-Pharma, BSP Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Antibody-drug Conjugates (ADCs) CMO and CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody-drug Conjugates (ADCs) CMO and CDMO.

The Antibody-drug Conjugates (ADCs) CMO and CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antibody-drug Conjugates (ADCs) CMO and CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Antibody-drug Conjugates (ADCs) CMO and CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Antibody-drug Conjugates (ADCs) CMO and CDMO Market Report

Report Metric	Details
Report Name	Antibody-drug Conjugates (ADCs) CMO and CDMO Market
Accounted market size in year	US$ 3863 million
Forecasted market size in 2031	US$ 12840 million
CAGR	19.0%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Cleavable linkers Non-cleavable linkers
Segment by Application	Solid Tumors Hematological Malignanciesncies
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Lonza Group, Merck KGaA, WuXi XDC, Abbvie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions, Axplora, Aji Bio-Pharma, BSP Pharmaceuticals, Cerbios-Pharma, Goodwin Biotechnology, TOT Biopharm, Huadong Medicine, Innovent Biologics, Shanghai Henlius Biotech
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody-drug Conjugates (ADCs) CMO and CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Antibody-drug Conjugates (ADCs) CMO and CDMO Market growing?

Ans: The Antibody-drug Conjugates (ADCs) CMO and CDMO Market witnessing a CAGR of 19.0% during the forecast period 2025-2031.

What is the Antibody-drug Conjugates (ADCs) CMO and CDMO Market size in 2031?

Ans: The Antibody-drug Conjugates (ADCs) CMO and CDMO Market size in 2031 will be US$ 12840 million.

Who are the main players in the Antibody-drug Conjugates (ADCs) CMO and CDMO Market report?

Ans: The main players in the Antibody-drug Conjugates (ADCs) CMO and CDMO Market are Lonza Group, Merck KGaA, WuXi XDC, Abbvie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions, Axplora, Aji Bio-Pharma, BSP Pharmaceuticals, Cerbios-Pharma, Goodwin Biotechnology, TOT Biopharm, Huadong Medicine, Innovent Biologics, Shanghai Henlius Biotech

What are the Application segmentation covered in the Antibody-drug Conjugates (ADCs) CMO and CDMO Market report?

Ans: The Applications covered in the Antibody-drug Conjugates (ADCs) CMO and CDMO Market report are Solid Tumors, Hematological Malignanciesncies

What are the Type segmentation covered in the Antibody-drug Conjugates (ADCs) CMO and CDMO Market report?

Ans: The Types covered in the Antibody-drug Conjugates (ADCs) CMO and CDMO Market report are Cleavable linkers, Non-cleavable linkers

Recommended Reports

ADC & Antibody Conjugates

CDMO & CMO Pharma

Cell & Gene Therapy

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Cleavable linkers

1.2.3 Non-cleavable linkers

1.3 Market by Application

1.3.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Solid Tumors

1.3.3 Hematological Malignanciesncies

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Perspective (2020-2031)

2.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Growth Trends by Region

2.2.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Antibody-drug Conjugates (ADCs) CMO and CDMO Historic Market Size by Region (2020-2025)

2.2.3 Antibody-drug Conjugates (ADCs) CMO and CDMO Forecasted Market Size by Region (2026-2031)

2.3 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Dynamics

2.3.1 Antibody-drug Conjugates (ADCs) CMO and CDMO Industry Trends

2.3.2 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Drivers

2.3.3 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Challenges

2.3.4 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Antibody-drug Conjugates (ADCs) CMO and CDMO Players by Revenue

3.1.1 Global Top Antibody-drug Conjugates (ADCs) CMO and CDMO Players by Revenue (2020-2025)

3.1.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Players (2020-2025)

3.2 Global Top Antibody-drug Conjugates (ADCs) CMO and CDMO Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue

3.4 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Concentration Ratio

3.4.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue in 2024

3.5 Global Key Players of Antibody-drug Conjugates (ADCs) CMO and CDMO Head office and Area Served

3.6 Global Key Players of Antibody-drug Conjugates (ADCs) CMO and CDMO, Product and Application

3.7 Global Key Players of Antibody-drug Conjugates (ADCs) CMO and CDMO, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Antibody-drug Conjugates (ADCs) CMO and CDMO Breakdown Data by Type

4.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Historic Market Size by Type (2020-2025)

4.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Forecasted Market Size by Type (2026-2031)

5 Antibody-drug Conjugates (ADCs) CMO and CDMO Breakdown Data by Application

5.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Historic Market Size by Application (2020-2025)

5.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (2020-2031)

6.2 North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025)

6.4 North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (2020-2031)

7.2 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025)

7.4 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (2020-2031)

8.2 Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2020-2025)

8.4 Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (2020-2031)

9.2 Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025)

9.4 Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (2020-2031)

10.2 Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025)

10.4 Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Lonza Group

11.1.1 Lonza Group Company Details

11.1.2 Lonza Group Business Overview

11.1.3 Lonza Group Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction

11.1.4 Lonza Group Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

11.1.5 Lonza Group Recent Development

11.2 Merck KGaA

11.2.1 Merck KGaA Company Details

11.2.2 Merck KGaA Business Overview

11.2.3 Merck KGaA Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction

11.2.4 Merck KGaA Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

11.2.5 Merck KGaA Recent Development

11.3 WuXi XDC

11.3.1 WuXi XDC Company Details

11.3.2 WuXi XDC Business Overview

11.3.3 WuXi XDC Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction

11.3.4 WuXi XDC Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

11.3.5 WuXi XDC Recent Development

11.4 Abbvie

11.4.1 Abbvie Company Details

11.4.2 Abbvie Business Overview

11.4.3 Abbvie Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction

11.4.4 Abbvie Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

11.4.5 Abbvie Recent Development

11.5 Piramal Pharma Solutions

11.5.1 Piramal Pharma Solutions Company Details

11.5.2 Piramal Pharma Solutions Business Overview

11.5.3 Piramal Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction

11.5.4 Piramal Pharma Solutions Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

11.5.5 Piramal Pharma Solutions Recent Development

11.6 Catalent

11.6.1 Catalent Company Details

11.6.2 Catalent Business Overview

11.6.3 Catalent Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction

11.6.4 Catalent Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

11.6.5 Catalent Recent Development

11.7 Sterling Pharma Solutions

11.7.1 Sterling Pharma Solutions Company Details

11.7.2 Sterling Pharma Solutions Business Overview

11.7.3 Sterling Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction

11.7.4 Sterling Pharma Solutions Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

11.7.5 Sterling Pharma Solutions Recent Development

11.8 Axplora

11.8.1 Axplora Company Details

11.8.2 Axplora Business Overview

11.8.3 Axplora Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction

11.8.4 Axplora Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

11.8.5 Axplora Recent Development

11.9 Aji Bio-Pharma

11.9.1 Aji Bio-Pharma Company Details

11.9.2 Aji Bio-Pharma Business Overview

11.9.3 Aji Bio-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction

11.9.4 Aji Bio-Pharma Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

11.9.5 Aji Bio-Pharma Recent Development

11.10 BSP Pharmaceuticals

11.10.1 BSP Pharmaceuticals Company Details

11.10.2 BSP Pharmaceuticals Business Overview

11.10.3 BSP Pharmaceuticals Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction

11.10.4 BSP Pharmaceuticals Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

11.10.5 BSP Pharmaceuticals Recent Development

11.11 Cerbios-Pharma

11.11.1 Cerbios-Pharma Company Details

11.11.2 Cerbios-Pharma Business Overview

11.11.3 Cerbios-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction

11.11.4 Cerbios-Pharma Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

11.11.5 Cerbios-Pharma Recent Development

11.12 Goodwin Biotechnology

11.12.1 Goodwin Biotechnology Company Details

11.12.2 Goodwin Biotechnology Business Overview

11.12.3 Goodwin Biotechnology Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction

11.12.4 Goodwin Biotechnology Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

11.12.5 Goodwin Biotechnology Recent Development

11.13 TOT Biopharm

11.13.1 TOT Biopharm Company Details

11.13.2 TOT Biopharm Business Overview

11.13.3 TOT Biopharm Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction

11.13.4 TOT Biopharm Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

11.13.5 TOT Biopharm Recent Development

11.14 Huadong Medicine

11.14.1 Huadong Medicine Company Details

11.14.2 Huadong Medicine Business Overview

11.14.3 Huadong Medicine Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction

11.14.4 Huadong Medicine Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

11.14.5 Huadong Medicine Recent Development

11.15 Innovent Biologics

11.15.1 Innovent Biologics Company Details

11.15.2 Innovent Biologics Business Overview

11.15.3 Innovent Biologics Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction

11.15.4 Innovent Biologics Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

11.15.5 Innovent Biologics Recent Development

11.16 Shanghai Henlius Biotech

11.16.1 Shanghai Henlius Biotech Company Details

11.16.2 Shanghai Henlius Biotech Business Overview

11.16.3 Shanghai Henlius Biotech Antibody-drug Conjugates (ADCs) CMO and CDMO Introduction

11.16.4 Shanghai Henlius Biotech Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

11.16.5 Shanghai Henlius Biotech Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Companies

Lonza Group

Merck KGaA

WuXi XDC

AbbVie

Piramal Pharma Solutions

Catalent

Sterling Pharma Solutions

Axplora

Aji Bio-Pharma

BSP Pharmaceuticals

Cerbios-Pharma

Goodwin Biotechnology

TOT BIOPHARM

Huadong Medicine

Innovent Biologics

Shanghai Henlius Biotech

List of Tables

Table 1. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Cleavable linkers

Table 3. Key Players of Non-cleavable linkers

Table 4. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Region (2020-2025)

Table 8. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Region (2026-2031)

Table 10. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Trends

Table 11. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Drivers

Table 12. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Challenges

Table 13. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Restraints

Table 14. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Players (2020-2025)

Table 16. Global Top Antibody-drug Conjugates (ADCs) CMO and CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO as of 2024)

Table 17. Ranking of Global Top Antibody-drug Conjugates (ADCs) CMO and CDMO Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Antibody-drug Conjugates (ADCs) CMO and CDMO, Headquarters and Area Served

Table 20. Global Key Players of Antibody-drug Conjugates (ADCs) CMO and CDMO, Product and Application

Table 21. Global Key Players of Antibody-drug Conjugates (ADCs) CMO and CDMO, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Type (2020-2025)

Table 25. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Type (2026-2031)

Table 27. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Application (2020-2025)

Table 29. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Application (2026-2031)

Table 31. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2026-2031) & (US$ Million)

Table 46. Lonza Group Company Details

Table 47. Lonza Group Business Overview

Table 48. Lonza Group Antibody-drug Conjugates (ADCs) CMO and CDMO Product

Table 49. Lonza Group Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)

Table 50. Lonza Group Recent Development

Table 51. Merck KGaA Company Details

Table 52. Merck KGaA Business Overview

Table 53. Merck KGaA Antibody-drug Conjugates (ADCs) CMO and CDMO Product

Table 54. Merck KGaA Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)

Table 55. Merck KGaA Recent Development

Table 56. WuXi XDC Company Details

Table 57. WuXi XDC Business Overview

Table 58. WuXi XDC Antibody-drug Conjugates (ADCs) CMO and CDMO Product

Table 59. WuXi XDC Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)

Table 60. WuXi XDC Recent Development

Table 61. Abbvie Company Details

Table 62. Abbvie Business Overview

Table 63. Abbvie Antibody-drug Conjugates (ADCs) CMO and CDMO Product

Table 64. Abbvie Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)

Table 65. Abbvie Recent Development

Table 66. Piramal Pharma Solutions Company Details

Table 67. Piramal Pharma Solutions Business Overview

Table 68. Piramal Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Product

Table 69. Piramal Pharma Solutions Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)

Table 70. Piramal Pharma Solutions Recent Development

Table 71. Catalent Company Details

Table 72. Catalent Business Overview

Table 73. Catalent Antibody-drug Conjugates (ADCs) CMO and CDMO Product

Table 74. Catalent Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)

Table 75. Catalent Recent Development

Table 76. Sterling Pharma Solutions Company Details

Table 77. Sterling Pharma Solutions Business Overview

Table 78. Sterling Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Product

Table 79. Sterling Pharma Solutions Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)

Table 80. Sterling Pharma Solutions Recent Development

Table 81. Axplora Company Details

Table 82. Axplora Business Overview

Table 83. Axplora Antibody-drug Conjugates (ADCs) CMO and CDMO Product

Table 84. Axplora Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)

Table 85. Axplora Recent Development

Table 86. Aji Bio-Pharma Company Details

Table 87. Aji Bio-Pharma Business Overview

Table 88. Aji Bio-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Product

Table 89. Aji Bio-Pharma Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)

Table 90. Aji Bio-Pharma Recent Development

Table 91. BSP Pharmaceuticals Company Details

Table 92. BSP Pharmaceuticals Business Overview

Table 93. BSP Pharmaceuticals Antibody-drug Conjugates (ADCs) CMO and CDMO Product

Table 94. BSP Pharmaceuticals Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)

Table 95. BSP Pharmaceuticals Recent Development

Table 96. Cerbios-Pharma Company Details

Table 97. Cerbios-Pharma Business Overview

Table 98. Cerbios-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Product

Table 99. Cerbios-Pharma Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)

Table 100. Cerbios-Pharma Recent Development

Table 101. Goodwin Biotechnology Company Details

Table 102. Goodwin Biotechnology Business Overview

Table 103. Goodwin Biotechnology Antibody-drug Conjugates (ADCs) CMO and CDMO Product

Table 104. Goodwin Biotechnology Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)

Table 105. Goodwin Biotechnology Recent Development

Table 106. TOT Biopharm Company Details

Table 107. TOT Biopharm Business Overview

Table 108. TOT Biopharm Antibody-drug Conjugates (ADCs) CMO and CDMO Product

Table 109. TOT Biopharm Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)

Table 110. TOT Biopharm Recent Development

Table 111. Huadong Medicine Company Details

Table 112. Huadong Medicine Business Overview

Table 113. Huadong Medicine Antibody-drug Conjugates (ADCs) CMO and CDMO Product

Table 114. Huadong Medicine Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)

Table 115. Huadong Medicine Recent Development

Table 116. Innovent Biologics Company Details

Table 117. Innovent Biologics Business Overview

Table 118. Innovent Biologics Antibody-drug Conjugates (ADCs) CMO and CDMO Product

Table 119. Innovent Biologics Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)

Table 120. Innovent Biologics Recent Development

Table 121. Shanghai Henlius Biotech Company Details

Table 122. Shanghai Henlius Biotech Business Overview

Table 123. Shanghai Henlius Biotech Antibody-drug Conjugates (ADCs) CMO and CDMO Product

Table 124. Shanghai Henlius Biotech Revenue in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025) & (US$ Million)

Table 125. Shanghai Henlius Biotech Recent Development

Table 126. Research Programs/Design for This Report

Table 127. Key Data Information from Secondary Sources

Table 128. Key Data Information from Primary Sources

Table 129. Authors List of This Report

List of Figures

Figure 1. Antibody-drug Conjugates (ADCs) CMO and CDMO Picture

Figure 2. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Type: 2024 VS 2031

Figure 4. Cleavable linkers Features

Figure 5. Non-cleavable linkers Features

Figure 6. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Application: 2024 VS 2031

Figure 8. Solid Tumors Case Studies

Figure 9. Hematological Malignanciesncies Case Studies

Figure 10. Antibody-drug Conjugates (ADCs) CMO and CDMO Report Years Considered

Figure 11. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 12. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Region: 2024 VS 2031

Figure 14. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Players in 2024

Figure 15. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 16. The Top 10 and 5 Players Market Share by Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue in 2024

Figure 17. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 18. North America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Country (2020-2031)

Figure 19. United States Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. Canada Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Country (2020-2031)

Figure 23. Germany Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. France Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. U.K. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Italy Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Russia Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Nordic Countries Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Region (2020-2031)

Figure 31. China Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Japan Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. South Korea Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Southeast Asia Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. India Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Australia Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Country (2020-2031)

Figure 39. Mexico Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Brazil Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Share by Country (2020-2031)

Figure 43. Turkey Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Saudi Arabia Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. UAE Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Lonza Group Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

Figure 47. Merck KGaA Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

Figure 48. WuXi XDC Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

Figure 49. Abbvie Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

Figure 50. Piramal Pharma Solutions Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

Figure 51. Catalent Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

Figure 52. Sterling Pharma Solutions Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

Figure 53. Axplora Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

Figure 54. Aji Bio-Pharma Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

Figure 55. BSP Pharmaceuticals Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

Figure 56. Cerbios-Pharma Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

Figure 57. Goodwin Biotechnology Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

Figure 58. TOT Biopharm Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

Figure 59. Huadong Medicine Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

Figure 60. Innovent Biologics Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

Figure 61. Shanghai Henlius Biotech Revenue Growth Rate in Antibody-drug Conjugates (ADCs) CMO and CDMO Business (2020-2025)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Antibody Drug Conjugate ADC Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Peptide Drug Conjugates PDCs CDMO Service Market Research Report 2024

Global Antibody Drug Conjugate CDMO Market Research Report 2024

Antibody drug Conjugate for Cancer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Antibody drug Conjugates for Tumors Market Research Report 2024

Global ADC Drug CDMO Service Market Research Report 2024

Global ADC Linkers Market Research Report 2024

Global Antibody Drug Conjugates Contract Manufacturing Market Research Report 2025

Global Monoclonal Antibody ADC Drugs Market Research Report 2025

Global Antibody drug Conjugate ADC Payload Market Research Report 2025

Global HER2 Antibody Drug Conjugate Market Research Report 2025

Global HER2 ADC Drugs Market Research Report 2024

Global ADC Manufacturing Service Market Research Report 2025

Global Antibody Oligonucleotide Conjugates AOC Drug CDMO Market Research Report 2024

Global Antibody PMO Conjugates Market Research Report 2024

Global Highly Potent API HPAPI For Antibody drug Conjugate ADC Market Research Report 2025

ADC Platform Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Antibody oligonucleotide Conjugates AOCs Market Research Report 2024

Global Next Generation Antibody Therapeutics Market Research Report 2025

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-14Y6812

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-34O3983

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-9V17601

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22C17047

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions